<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>SSc &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/ssc/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Tue, 04 Jan 2022 07:15:44 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>SSc &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>2021-2025年中国吗替麦考酚酯市场研究报告:2020年销售额约9.2亿元</title>
		<link>https://www.yuanzhezixun.com/2021-2025nianzhongguomatimaikaofenzhishichangyanjiubaogao/</link>
		
		<dc:creator><![CDATA[Timlee]]></dc:creator>
		<pubDate>Wed, 21 Jul 2021 08:13:57 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[CELLCEPT]]></category>
		<category><![CDATA[MMF]]></category>
		<category><![CDATA[mycophenolate mofetil]]></category>
		<category><![CDATA[SLE]]></category>
		<category><![CDATA[SSc]]></category>
		<category><![CDATA[systemic lupus erythematosus]]></category>
		<category><![CDATA[systemic sclerosis]]></category>
		<category><![CDATA[中美华东制药]]></category>
		<category><![CDATA[免疫抑制剂]]></category>
		<category><![CDATA[双鹭药业]]></category>
		<category><![CDATA[吗替麦考酚酯]]></category>
		<category><![CDATA[器官移植]]></category>
		<category><![CDATA[川抗制药]]></category>
		<category><![CDATA[扶异]]></category>
		<category><![CDATA[抗生素]]></category>
		<category><![CDATA[欣复同]]></category>
		<category><![CDATA[炎性肌病]]></category>
		<category><![CDATA[狼疮性肾炎]]></category>
		<category><![CDATA[糖皮质激素助减剂]]></category>
		<category><![CDATA[系统性硬化症]]></category>
		<category><![CDATA[系统性红斑狼疮]]></category>
		<category><![CDATA[系统性血管炎]]></category>
		<category><![CDATA[罗氏]]></category>
		<category><![CDATA[赛可平]]></category>
		<category><![CDATA[邛崃天银制药]]></category>
		<category><![CDATA[风湿性疾病]]></category>
		<category><![CDATA[骁悉]]></category>
		<category><![CDATA[麦考芬]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=25214</guid>

					<description><![CDATA[吗替麦考酚酯（mycophenolate mofetil，MMF）是一种淋巴细胞增殖强效免疫抑制剂。CRI元哲的调研数据显示，2016-2020年中国市场吗替麦考酚酯销售额逐年上升。2020年，受新冠疫情对医疗整体诊疗服务的冲击，销售额增幅有所减少，但销售额仍然达到9.21亿元，在2016-2020年的CAGR为6.54%。CRI元哲预计在2021-2025年随着新冠疫情的缓解，中国市场吗替麦考酚酯销售额将有恢复性的增长。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
